Total raised
$2.1M
Last: Pre-Seed 2023-01
Stage
Pre-Seed
Founded
2023
Headcount
2
HQ
Nazareth, Israel
Sector
Health Tech & Life Sciences
About
Orsight Pharma develops a breakthrough small molecule treatment designed to preserve vision and prevent blindness through a novel VEGF-independent mechanism. This drug offers a ray of hope, especially for those who have not seen satisfactory results with existing treatments. The company's product not only stands to benefit patients unresponsive to current therapies but also has the potential to enhance visual outcomes when used in combination with them.
Funding history · 1 round · $2.1M total
2023-01
Pre-Seed
$2.1M
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is Orsight Pharma's primary focus?
- Orsight Pharma develops a small molecule treatment for Neovascular Age-Related Macular Degeneration, aiming to preserve vision and prevent blindness through a novel VEGF-independent mechanism.
- When was Orsight Pharma founded?
- Orsight Pharma was founded in October 2023.
- What was Orsight Pharma's first funding round?
- Orsight Pharma secured a Pre-Seed round in January 2023, raising a total of $2,100,000. NGT HealthCare II was a lead investor in this round.
- What is the current employee count for Orsight Pharma?
- Orsight Pharma currently has 2 employees.
- Where is Orsight Pharma headquartered?
- Orsight Pharma is headquartered in Nazareth, Israel.
- Has Orsight Pharma received any grants?
- Yes, Orsight Pharma received a grant from the IIA in May 2024.
- What is Orsight Pharma's current product stage?
- Orsight Pharma's product is currently in the R&D stage.
- Who is a founder of Orsight Pharma?
- Mariana Truman is a founder of Orsight Pharma.
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Business model
B2C